Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study

Ixekizumab is a humanized IgG4 monoclonal antibody that binds with high affinity and specificity to IL-17A. This medication is currently approved for the treatment of plaque Ps, ankylosing spondylitis, and psoriatic arthritis.